This article was originally published in The Gray Sheet
Firm raises $11.8 mil. in a private placement of 1.5 mil. shares to institutional investors. Lincolnshire, Illinois-based Aksys is conducting clinical trials of its PHD personal hemodialysis system and expects to submit a 510(k) by the end of October (1"The Gray Sheet" Jan. 10, In Brief). Proceeds will support pre-commercialization activities, including a planned ramp-up in sales staff and manufacturing. U.S. Bancorp Piper Jaffray was placement agent for the financing
You may also be interested in...
Enrolls 24 patients in a six-month clinical study of its PHD personal hemodialysis system to support a future 510(k) submission to FDA. The three-phase trial is being conducted at dialysis clinics located in Washington, Missouri and Mississippi
Suspension of heartburn remedy ranitidine looming in the EU as the European Medicines Agency stands by its original decision.
Illumina announced on 21 September it will buy back Grail, which is planning to commercialize its multi-cancer early detection blood test Galleri in 2021. See what Illumina’s CEO Francis deSouza said about it here.